BD Diagnostics, the world leader in infectious disease diagnostics, announces the immediate availability of the CLIA-waived BD Chek™ Strep A test (Cat. No. 256018). Built on lateral flow technology, the BD Chek Strep A test features simplified workflow, easy-to-read results, convenient room temperature storage and rapid time-to-results in just 5 minutes. Most importantly, the test is highly accurate: 97.7% overall accuracy, 95.1% sensitivity and 99.0% specificity. In addition to the reagent stand provided in the kit, a creative separate workstation is also included in each kit. The reusable test tube workstation allows users to perform 5 tests at a time for the convenience of batch testing. The BD Chek Strep A test provides an all-inclusive package with 25 individually pouched test strips, kit swabs and sufficient liquid controls. For more information contact your local BD representative or call toll-free at 1-800-638-8663.

BD and BD Chek are trademarks of Becton, Dickinson and Company. © 2004 BD.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.